Harpoon Therapeutics, Inc. Common Stock
HARP
HARP was delisted on the 8th of March, 2024.
79 hedge funds and large institutions have $341M invested in Harpoon Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 24 increasing their positions, 21 reducing their positions, and 8 closing their positions.
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
14% more funds holding
Funds holding: 69 → 79 (+10)
14% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 21
2% more capital invested
Capital invested by funds: $335M → $341M (+$5.62M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
27% less call options, than puts
Call options by funds: $762K | Put options by funds: $1.05M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.45M |
| 2 |
BlackRock
New York
|
+$1.92M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.58M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$1.53M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$759K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$14M |
| 2 |
Millennium Management
New York
|
-$3.31M |
| 3 |
AG
Artal Group
Luxembourg
|
-$1.44M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.3M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.08M |
HARP Hedge Fund Activity: Q3 2020 in Review
79 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Harpoon Therapeutics, Inc. Common Stock (HARP) for Q3 2020, worth a combined $341M — up 1.7% from $335M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new HARP positions and 8 closed out — a net gain of 10 holders — while 24 added to existing stakes and 21 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $7.45M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $14M sold.
- 79 institutional investors held Harpoon Therapeutics, Inc. Common Stock (HARP) as of Q3 2020, up from 69 in Q2 2020.
- Funds reported $341M of Harpoon Therapeutics, Inc. Common Stock stock for Q3 2020, up 1.7% quarter-over-quarter.
- 18 funds opened new Harpoon Therapeutics, Inc. Common Stock positions in Q3 2020 and 8 closed out, a net change of +10 holders.
- The largest Harpoon Therapeutics, Inc. Common Stock buyer in Q3 2020 was Point72 Asset Management, an estimated $7.45M added.
- The largest Harpoon Therapeutics, Inc. Common Stock seller in Q3 2020 was Consonance Capital Management, an estimated $14M sold.
Based on aggregated 13F filings for Q3 2020.